SALMONELLA

VolverVolver

Resultados 67 resultados LastUpdate Última actualización 05/02/2023 [12:24:00] pdf PDF xls XLS

Solicitudes publicadas en los últimos 90 días / Applications published in the last 90 days



Página1 de 3 nextPage   por página


SHIGELLA-TETRAVALENT (SHIGELLA4V) BIOCONJUGATE

NºPublicación: CN115697396A 03/02/2023

Solicitante:

葛兰素史克生物有限公司

WO_2021255684_A1

Resumen de: WO2021255684A1

A composition comprising Shigella-Tetravalent (4-valent Shigella) bioconjugates. That encompasses the Shigella O-polysaccharide antigens of serotypes Shigella flexneri 2a, 3a, 6 and Shigella sonnei covalently linked to the protein carrier.

traducir

Sampling systems and related materials and methods

NºPublicación: AU2022283757A1 02/02/2023

Solicitante:

BIORA THERAPEUTICS INC

JP_2023002585_PA

Resumen de: AU2022283757A1

Sampling systems that include an absorbent material a preservative, such as an analyte preservative, as well as related materials and methods, are disclosed.

traducir

Salmonella strain for treating cancer and use thereof

NºPublicación: AU2020454144A1 02/02/2023

Solicitante:

INDUSTRY FOUNDATION OF CHONNAM NATIONAL UNIV

WO_2021256599_A1

Resumen de: AU2020454144A1

The present invention relates to a Salmonella strain that selectively acts on cancer for the treatment of cancer, and a composition for preventing or treating cancer comprising same. Specifically, the Salmonella strain according to the present invention has a tumor-suppressing effect, but the viability thereof is significantly low in normal organs, and thus can have a significant anticancer effect compared to the conventional invention.

traducir

Autotransporter system

NºPublicación: AU2021291618A1 02/02/2023

Solicitante:

PROKARIUM LTD

WO_2021255480_A1

Resumen de: AU2021291618A1

The present invention provides for a modified autotransporter and the use of genetically engineered microorganisms comprising said modified autotransporters in the treatment of infectious and neoplastic disease. The present invention therefore also relates to vaccine and immunotherapeutic compositions comprising said genetically engineered microorganism.

traducir

METHODS OF INACTIVATING PATHOGENS

NºPublicación: WO2023009213A1 02/02/2023

Solicitante:

GRIGNARD PURE LLC [US]

Resumen de: WO2023009213A1

This disclosure relates to a method for sanitizing a space. The method includes applying a composition containing triethylene glycol into a space containing a pathogen (e.g., a Staphylococcus, a Pseudomonas, a Listeria, Salmonella, Klebsiella, a mycobacterium, a mold, or a spore) in an amount effective to inactivate the pathogen.

traducir

A METHOD FOR PRODUCING COMPLEXES OF PROTEINS WITH BACTERIAL LIPOPOLYSACCHARIDES, THE USE THEREOF, A VACCINE COMPRISING AN LPS/PROTEIN IMMUNOGENIC COMPLEX AND A METHOD FOR PRODUCING THE VACCINE

NºPublicación: WO2023007456A1 02/02/2023

Solicitante:

BIOVETIKA SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA [PL]

Resumen de: WO2023007456A1

The object of the invention is a method for producing bacterial lipopolysaccharide (LPS)/protein immune complexes, the use of the LPS/protein complex to induce an immune response, a method for producing a veterinary vaccine comprising the LPS/protein immune complex and a veterinary vaccine produced by this method.

traducir

CANCER THERAPY WITH LIVE ATTENUATED BACTERIA

NºPublicación: WO2023006879A1 02/02/2023

Solicitante:

PROKARIUM LTD [GB]

Resumen de: WO2023006879A1

The present invention relates to the field of cancer therapy. In particular, the present invention relates to a first composition comprising a live attenuated bacterium for use in the treatment, prevention, reduction, inhibition, prevention of recurrence, or control of a neoplastic disease in a subject being or intended to be administered a second composition comprising a live attenuated bacterium, said bacterium being the same or different to that of the first composition and methods thereof.

traducir

COMPOSITIONS AND METHODS FOR DETECTING GASTROINTESTINAL PATHOGENS

NºPublicación: WO2023010008A1 02/02/2023

Solicitante:

GEN PROBE INCORPORATED [US]

Resumen de: WO2023010008A1

Compositions, methods, kits, and uses are provided for detecting the presence of Salmonella, Shigella, Campylobacter, and Shigatoxigenic Eschelichia coli (STEC) in samples. In some embodiments, the compositions, methods, kits, and uses comprise one or more oligonucleotides or the use of one or more oligonucleotides. In some embodiments, the method is carried out as a multiplex assay with separate primers/probes for C.jejuni and C.coli. Some of the oligonucleotides contain inosine and/or contain 5-methylcytosine substituted nucleotides. Described is the use of cyclodextrin and/or Polysorbate 20 in the amplification reactions.

traducir

CANCER THERAPY WITH LIVE ATTENUATED BACTERIA

NºPublicación: EP4124342A1 01/02/2023

Solicitante:

PROKARIUM LTD [GB]

Resumen de: EP4124342A1

The present invention relates to the field of cancer therapy. In particular, the present invention relates to a method of preventing, treating or inhibiting the development of neoplastic disease in a subject.

traducir

VACCINE COMPOSITION COMPRISING CAPSULAR POLYSACCHARIDE-PROTEIN CONJUGATE DERIVED FROM SALMONELLA TYPHI

NºPublicación: KR20230013934A 27/01/2023

Solicitante:

에스케이바이오사이언스주

WO_2023003329_PA

Resumen de: WO2023003329A1

The present invention relates to a vaccine composition comprising a capsular polysaccharide-protein conjugate derived from Salmonella typhi, wherein the optimal culture conditions for Salmonella typhi growth and Vi capsular polysaccharide expression were established, the purified Vi capsular polysaccharide was conjugated to a conjugate protein to produce a conjugate having a specific average molecular weight, and it was confirmed that a Vi capsular polysaccharide-conjugated protein conjugate of the present invention had excellent immunogenicity. A method for producing the Vi capsular polysaccharide-conjugated protein conjugate of the present invention, and a conjugate produced thereby can be used for the prevention of typhoid.

traducir

VACCINE COMPOSITION COMPRISING CAPSULAR POLYSACCHARIDE-PROTEIN CONJUGATE DERIVED FROM SALMONELLA TYPHI

NºPublicación: WO2023003329A1 26/01/2023

Solicitante:

SK BIOSCIENCE CO LTD [KR]

KR_20230013934_PA

Resumen de: WO2023003329A1

The present invention relates to a vaccine composition comprising a capsular polysaccharide-protein conjugate derived from Salmonella typhi, wherein the optimal culture conditions for Salmonella typhi growth and Vi capsular polysaccharide expression were established, the purified Vi capsular polysaccharide was conjugated to a conjugate protein to produce a conjugate having a specific average molecular weight, and it was confirmed that a Vi capsular polysaccharide-conjugated protein conjugate of the present invention had excellent immunogenicity. A method for producing the Vi capsular polysaccharide-conjugated protein conjugate of the present invention, and a conjugate produced thereby can be used for the prevention of typhoid.

traducir

TOOLS AND METHODS TO DETECT AND ISOLATE COLIBACTIN PRODUCING BACTERIA

NºPublicación: US2023029322A1 26/01/2023

Solicitante:

CONSEJO SUPERIOR INVESTIGACION [ES]
FUNPACION CIENTIFICA DE LA ASOC ESPANOLA CONTRA EL CANCER [ES]

WO_2021110833_A1

Resumen de: US2023029322A1

The invention relates to the field of medical diagnosis, particularly to methods and antibodies useful for the identification of colibactin producing bacteria (pks+ bacteria). Herein are disclosed peptides and antibodies that allow for the detection and isolation of pks+ bacteria, as well as uses and methods of use of said peptides and antibodies.

traducir

COMPOSITION COMPRISING BETA-GLUCANS AND ALPHA-FUCANS FOR IMPROVING GUT HEALTH AND ANIMAL PERFORMANCE AND METHODS OF MAKING THE SAME

NºPublicación: WO2023002252A1 26/01/2023

Solicitante:

BIOATLANTIS LTD [IE]

Resumen de: WO2023002252A1

The present invention relates to a composition and methods comprising an amount of β-glucans and α-fucans, wherein the combination is synergistic to at least one of: increase growth of beneficial microbes and reduced levels of harmful microbes selected from E. coli or Salmonella in animal or human intestines, improve gut structure, reduce gut inflammation, improved nutrient digestibility, improve mineral absorption and growth performance, or reduce gut infection and inflammation.

traducir

Sensing Chip with Fluidic Device

NºPublicación: AU2022204265A1 19/01/2023

Solicitante:

KAO HSI TENG [TW]

CN_115508426_PA

Resumen de: AU2022204265A1

A sensing chip with fluidic device includes a substrate with a first area and a second area, a field effect transistor is arranged in the second area of the substrate and is electrically connected with the field effect transistor. The fluidic device includes an insulation layer with a window to expose the surface of substrate in the second area. A second gate electrode is arranged in the window of the isolation layer on the second area of the substrate. The sample is placed in the fluidic device to contact with the second gate electrode, and the receptor(s) on the metal layer will capture the target object in the sample, so the voltage of the metal layer will change with amount of the target object captured by the receptor(s). Thus, the concentration of the target object(s) in the sample may obtain by the changes of the voltage of the metal layer. 3 0 50 4010 206 m-40214 lOB 1OA Fig.lIA

traducir

ENGINEERED S. TYPHIMURIUM AND USES THEREOF

NºPublicación: WO2023287770A2 19/01/2023

Solicitante:

VIRGINIA POLYTECHNIC INSTITUTE AND STATE UNIV [US]

Resumen de: WO2023287770A2

Described herein are engineered Salmonella Typhimurium (S. Typhimurium) bacteria and uses thereof. In some embodiments, the engineered S. Typhimurium bacteria comprises an exogenous collagenase. Also described in exemplary embodiments herein methods of using the engineered S. Typhimurium bacteria, such as part of a cancer therapy.

traducir

DETOXIFIED LIPOPOLYSACCHARIDES (LPS), NATURALLY NON-TOXIC LPS, AND USES THEREOF

NºPublicación: EP4117790A1 18/01/2023

Solicitante:

HEPHAISTOS PHARMA [FR]

CA_3171408_A1

Resumen de: WO2021180972A1

The invention relates to an enriched population of modified lipopolysaccharide (LPS) molecular species being: - devoid of phosphate group at position C1 of the reducing end of their lipid A domain; and - substituted at position C6' of the non-reducing end of their lipid A domain by a hydrophilic moiety, with the proviso that said hydrophilic moiety is not a hydroxyl group. It also relates to compositions comprising the enriched population of modified LPS; and uses of naturally-occurring LPS molecular species and/or enriched population of modified LPS molecular species for treating and/or preventing cancer, inflammatory diseases or infectious diseases, and for stimulating an immune response or vaccinating a subject.

traducir

LIVE SALMONELLA TYPHI VECTORS ENGINEERED TO EXPRESS PROTEIN ANTIGENS AND METHODS OF USE THEREOF

NºPublicación: EP4114451A1 11/01/2023

Solicitante:

UNIV MARYLAND [US]
NAT RES COUNCIL CANADA [CA]

AU_2021230603_PA

Resumen de: WO2021178891A1

The present invention provides compositions and methods of inducing an immune response in a subject in need thereof, comprising administering to the subject an immunologically-effective amount of a live Salmonella Typhi vector, wherein the Salmonella Typhi vector has been engineered to express one or more antigens; an outer membrane folding protein Bam A or a fragment or variant thereof; and a lipid A deacylase PagL or a fragment or variant thereof, wherein the Salmonella Typhi vector is capable of delivering the antigen to a mucosal tissue via an outer membrane vesicle when administered to a subject.

traducir

LIVE SALMONELLA TYPHI VECTORS ENGINEERED TO EXPRESS CANCER PROTEIN ANTIGENS AND METHODS OF USE THEREOF

NºPublicación: EP4114918A1 11/01/2023

Solicitante:

UNIV MARYLAND [US]
IRAZU BIO LLC [US]

AU_2021230602_PA

Resumen de: WO2021178888A1

The present invention provides compositions and methods for inducing an immune response in a subject in need thereof, comprising administering to the subject an immunologically-effective amount of a live Salmonella Typhi vector, wherein the Salmonella Typhi vector has been engineered to express one or more cancer antigens. In some aspects the vector has been engineered to express an outer membrane folding protein Bam A or a fragment or variant thereof; and a lipid A deacylase PagL or a fragment or variant thereof, wherein the Salmonella Typhi vector is capable of delivering the antigen to a mucosal tissue or subcutaneously to dendritic cells via an outer membrane vesicle when administered to a subject.

traducir

SYSTEMS FOR OBTAINING SAMPLES USING INGESTIBLE DEVICES

NºPublicación: JP2023002585A 10/01/2023

Solicitante:

ビオラ・セラピューティクス・インコーポレイテッド

AU_2022283757_A1

Resumen de: WO2018035394A1

Ingestible devices configured to obtain samples when present in the GI tract of a subject, as well as related systems and methods, are disclosed. Sampling systems that include an absorbent material a preservative, such as an analyte preservative, as well as related materials and methods, are also disclosed.

traducir

Reduction of viral disease transmission by avian antibodies

NºPublicación: AU2021267035A1 05/01/2023

Solicitante:

CAMAS INCORPORATED

WO_2021226358_A1

Resumen de: AU2021267035A1

Formulations of egg powders with avian antibodies that act as mucosal protectants are provided. The formulations are effective for protecting the mucosal membranes in the pharyngeal area of an individual from viral infections. Formulations effective for reducing infections of SARS-CoV-2 in individuals are provided. Formulations are also effective for reducing transmission of viral disease. The formulations are tablets, candies, gummies, throat lozenges, and powders for administering to the pharyngeal area. Methods for administering the formulations for reducing viral disease such as Covid-19 are disclosed.

traducir

ANTIBACTERIAL FORMULATION MADE OF A MIXTURE OF BACTERIOPHAGES, USE THEREOF, AND METHOD FOR PREVENTING OR TREATING DISEASES CAUSED BY SALMONELLA SPP. IN BREEDING ANIMALS, BY ORALLY ADMINISTERING THE FORMULATION

NºPublicación: EP4111865A1 04/01/2023

Solicitante:

PHAGELAB CHILE SPA [CL]

WO_2022241579_PA

Resumen de: EP4111865A1

The invention corresponds to an antibacterial formulation comprising a mixture of bacteriophages having lytic activity against strains of Salmonella spp. and a pharmaceutically and veterinarily acceptable vehicle, pH stabilizer and/or excipients. This formulation is for the prevention and treatment of infectious diseases caused by Salmonella spp. and different serovars; use and method for preventing or treating infectious diseases caused by Salmonella spp. in farm animals because it comprises administering the antibacterial formulation to a non-human animal orally.

traducir

YjeK YjeK gene deleted Salmonella typhimurium strain and Salmonella vaccine composition comprising the same

NºPublicación: KR20220170779A 30/12/2022

Solicitante:

INNOVAC [KR]

WO_2022270953_PA

Resumen de: WO2022270953A1

The present invention relates to a Salmonella typhimurium strain having YjeK gene deleted therefrom and to uses thereof. More specifically, the present invention relates to: a novel Salmonella typhimurium strain; and a vaccine composition, an immunogenic composition, and a feed composition comprising same. It was confirmed that the Salmonella typhimurium strain having YjeK gene deleted therefrom according to the present invention can effectively prevent Salmonella infection, thereby remarkably increasing a survival rate of an individual. This means that when the Salmonella typhimurium strain having YjeK gene deleted therefrom of the present invention is used as a vaccine, diseases related to Salmonella infection can be effectively prevented such that the present invention can be used in various ways in the field of livestock disease control.

traducir

ATTENUATED SALMONELLA, VACCINES, AND DELIVERY PLATFORM

NºPublicación: WO2022271976A1 29/12/2022

Solicitante:

ELANCO US INC [US]

Resumen de: WO2022271976A1

The present invention provides an intracellular delivery platform comprising an attenuated bacterium carrying a self-amplifying nucleic acid encoding a therapeutic biomolecule. The therapeutic biomolecule has a desired activity or effect such as treating or preventing an infection, disease or disorder, or eliciting protective immunity against a pathogenic or parasitic organism. Genetically modified and attenuated bacteria, particularly Salmonella bacteria, are provided. Methods for intracellular and systemic delivery of one or more therapeutic biomolecule are provided. Self-amplifying nucleic acids are provided.

traducir

SALMONELLA TYPHIMURIUM STRAIN HAVING YJEK GENE DELETED THEREFROM AND SALMONELLA VACCINE COMPOSITION COMPRISING SAME

NºPublicación: WO2022270953A1 29/12/2022

Solicitante:

INNOVAC CO [KR]

KR_20220170779_PA

Resumen de: WO2022270953A1

The present invention relates to a Salmonella typhimurium strain having YjeK gene deleted therefrom and to uses thereof. More specifically, the present invention relates to: a novel Salmonella typhimurium strain; and a vaccine composition, an immunogenic composition, and a feed composition comprising same. It was confirmed that the Salmonella typhimurium strain having YjeK gene deleted therefrom according to the present invention can effectively prevent Salmonella infection, thereby remarkably increasing a survival rate of an individual. This means that when the Salmonella typhimurium strain having YjeK gene deleted therefrom of the present invention is used as a vaccine, diseases related to Salmonella infection can be effectively prevented such that the present invention can be used in various ways in the field of livestock disease control.

traducir

SENSING CHIP WITH FLUIDIC DEVICE

Nº publicación: EP4109086A1 28/12/2022

Solicitante:

KAO HSI TENG [TW]

AU_2022204265_A1

Resumen de: EP4109086A1

A sensing chip with fluidic device (1) includes a substrate (10) with a first area (10A) and a second area (10B), a second gate electrode (40) is arranged in the second area of the substrate and is electrically connected with the field effect transistor (20). The fluidic device includes an insulation layer (30) with a window (302) to expose the surface of substrate in the second area. A second gate electrode is arranged in the window of the isolation layer on the second area of the substrate. The sample is placed in the fluidic device to contact with the second gate electrode, and the receptor(s) on the metal layer will capture the target object in the sample, so the voltage of the metal layer will change with amount of the target object captured by the receptor(s). Thus, the concentration of the target object(s) in the sample may obtain by the changes of the voltage of the metal layer.

traducir

Página1 de 3 nextPage por página

punteroimgVolver